CY1112775T1 - USE OF VALERIAN OSTRADIOLIS IN CONNECTION WITH DIENOGEST FOR ORAL TREATMENT OF MUTRAL DISORDER BLOOD TREATMENT IN AITITA - Google Patents

USE OF VALERIAN OSTRADIOLIS IN CONNECTION WITH DIENOGEST FOR ORAL TREATMENT OF MUTRAL DISORDER BLOOD TREATMENT IN AITITA

Info

Publication number
CY1112775T1
CY1112775T1 CY20121100460T CY121100460T CY1112775T1 CY 1112775 T1 CY1112775 T1 CY 1112775T1 CY 20121100460 T CY20121100460 T CY 20121100460T CY 121100460 T CY121100460 T CY 121100460T CY 1112775 T1 CY1112775 T1 CY 1112775T1
Authority
CY
Cyprus
Prior art keywords
dienogest
daily dose
dose units
estradiol valerate
combination
Prior art date
Application number
CY20121100460T
Other languages
Greek (el)
Inventor
Susan Zeun
Pol Boudes
Jan Endrikat
Angelo Secci
Holger Zimmermann
Original Assignee
Bayer Pharma Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37678725&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1112775(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP05022324A external-priority patent/EP1787649B1/en
Application filed by Bayer Pharma Aktiengesellschaft filed Critical Bayer Pharma Aktiengesellschaft
Publication of CY1112775T1 publication Critical patent/CY1112775T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to the use of estradiol valerate combined with 17a- cyanomethyl-17-ß-hydroxyestra-4,9-diene-3on (dienogest) for producing a multi-phase combination preparation for the oral therapy of the dysfunctional uterine bleeding in the form of oral contraceptives. Said combination of estradiol valerate with dienogest comprises a first phase consisting of 2 daily dose units of estradiol valerate at 3 mg, a second phase consisting of 2 groups of daily dose units, whereby the first group contains 5 daily dose units of a combination of 2 mg estradiol valerate and 2 mg of dienogest and the second group contains 17 daily dose units consisting of a combination of 2 mg of estradiol valerate and 3 mg dienogest, a third phase consisting of 2 daily dose units having 1 mg estradiol valerate and an additional phase consisting of 2 daily dose units on a pharmaceutically harmless placebo. All of the daily dose units of the multi-phase combination and the pharmaceutically harmless placebo correspond to 28 days. The duration of application comprises at least one menstruation cycle and is dependent on individual wishes of the woman with respect to contraception.
CY20121100460T 2005-10-13 2012-05-18 USE OF VALERIAN OSTRADIOLIS IN CONNECTION WITH DIENOGEST FOR ORAL TREATMENT OF MUTRAL DISORDER BLOOD TREATMENT IN AITITA CY1112775T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05022324A EP1787649B1 (en) 2005-10-13 2005-10-13 Use of estradiolvalerate and dienogest for oral treatment of dysfunctional uterine bleeding in a contraceptive method
US72759205P 2005-10-17 2005-10-17
EP06791828A EP1937274B1 (en) 2005-10-13 2006-09-05 Use of estradiol valerate combined with dienogest for oral therapy of dysfunctional uterine bleeding in the form of oral contraceptives

Publications (1)

Publication Number Publication Date
CY1112775T1 true CY1112775T1 (en) 2016-02-10

Family

ID=37678725

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100460T CY1112775T1 (en) 2005-10-13 2012-05-18 USE OF VALERIAN OSTRADIOLIS IN CONNECTION WITH DIENOGEST FOR ORAL TREATMENT OF MUTRAL DISORDER BLOOD TREATMENT IN AITITA

Country Status (9)

Country Link
EP (1) EP1937274B1 (en)
AT (1) ATE546144T1 (en)
CY (1) CY1112775T1 (en)
DK (1) DK1937274T3 (en)
ES (1) ES2382459T3 (en)
PL (1) PL1937274T3 (en)
PT (1) PT1937274E (en)
SI (1) SI1937274T1 (en)
WO (1) WO2007042111A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201316144D0 (en) * 2013-09-11 2013-10-23 Crown Packaging Technology Inc Universal seaming chuck

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4429374C1 (en) * 1994-08-12 1996-02-01 Jenapharm Gmbh Pharmaceutical preparations for contraception / hormone substitution with biogenic estrogen component
DE19540253C2 (en) * 1995-10-28 1998-06-04 Jenapharm Gmbh Multi-phase preparation for contraception based on natural estrogens
US6251956B1 (en) 1998-08-20 2001-06-26 Ortho Pharmaceutical Corporation Combination progestin oral contraceptive regimen
DE102004019743B4 (en) * 2004-04-20 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Multiphase preparation for contraception based on natural estrogen

Also Published As

Publication number Publication date
SI1937274T1 (en) 2012-06-29
PT1937274E (en) 2012-05-28
EP1937274B1 (en) 2012-02-22
WO2007042111A3 (en) 2007-10-11
ES2382459T3 (en) 2012-06-08
ATE546144T1 (en) 2012-03-15
EP1937274A2 (en) 2008-07-02
DK1937274T3 (en) 2012-06-18
WO2007042111A2 (en) 2007-04-19
PL1937274T3 (en) 2012-07-31

Similar Documents

Publication Publication Date Title
EA200900491A1 (en) USE OF ESTRADIOL VALERAT OR 17B-ESTRADIOL IN COMBINATION WITH DIENOGEST FOR ORAL TREATMENT TO MAINTAIN AND / OR INCREASE SEXUAL TREATMENT IN THE SPECIAL WOMAN
HRP20070188B1 (en) Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive
AR049112A1 (en) COMPOSITIONS, METHODS AND KIT, FOR THE TREATMENT OF PREMENSTRUAL DYSPHORIC DISORDER
AR048722A1 (en) TREATMENT OF DISRUPTION HEMORRAGY IN EXTENDED ANTI-CONCEPTIVE REGIMES
NO20080824L (en) Oral birth control with trimegestone
RS50972B (en) Pharmaceutical composition containing gestagens and/or estrogens and 5-methyl-(6s)-tetrahydrofolate
HUP0402142A2 (en) Composition of estrogen/gestagen combination, preparation and application thereof
ES2348038T5 (en) Polyphasic preparation for contraception based on a natural estrogen
CR8010A (en) EXTENDED TRANSDERMAL CONTRACEPTIVE REGIMES
CY1111406T1 (en) USE OF VALERIC OSTRADIOLIS OR OSTRADIOLIS IN COMBINATION WITH DIAGNOSTIC FOR ORAL TREATMENT OF BLOOD OSTRIPSI
CY1112775T1 (en) USE OF VALERIAN OSTRADIOLIS IN CONNECTION WITH DIENOGEST FOR ORAL TREATMENT OF MUTRAL DISORDER BLOOD TREATMENT IN AITITA
EA200701389A1 (en) SOLID ORAL MEDICAL FORM FOR CONTRACEPTION
TR200401810T4 (en) Use of fsh for infertility treatment
AR049195A1 (en) USE OF A COMBINATION OF ETHINYLESTRADIOL AND ACETATE OF CLORMADINONE FOR THE PREPARATION OF A MEDICINAL PRODUCT
EA200701091A1 (en) OPTICAL PHARMACEUTICALS
TW200638951A (en) Solid oral pharmaceutical form for contraception
RS50849B (en) Use of estradiolvalerate and dienogest for oral treatment of dysfunctional uterine bleeding in a contraceptive method
PE20070769A1 (en) PROCEDURE FOR THE PRODUCTION OF A MONOPHASIC PHARMACEUTICAL PREPARATION FOR ORAL THERAPY OF DYSFUNCTIONAL UTERINE HEMORRHAGE
BR0311209A (en) Method of producing pharmaceutical dosage units for oral administration, use of etonogestrel, and tablet
CL2023000450A1 (en) New composition of modified release oral contraceptive
RU2008149412A (en) USE OF DROSPIRENONE TO PREVENT HIGH BLOOD PRESSURE IN PATIENTS WITH PREHYPERTENSION
TH148141A (en) Combination of estradiolvalerate or estradiol with dienogest for oral therapy in malfunctioning uterine bleeding In combination with oral contraceptives
TH80557B (en) Pharmaceutical products for oral contraception
TH80558A (en) Solid oral dosage forms for birth control
MD2733F1 (en)   Method of treatment of menstrual cycle disorders associated with chronic viral hepatitis